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Abstract
Introduction: In December 2010, the World Health Organization recommended a single Xpert MTB/RIF assay as the initial
diagnostic in people suspected of HIV-associated or drug resistant tuberculosis. Few data are available on the impact of this
recommendation on patient outcomes. We describe the diagnostic follow-up, clinical characteristics and outcomes of a
cohort of tuberculosis suspects screened using a single point-of-care Xpert.
Methods: Consecutive tuberculosis suspects at a primary care clinic in Johannesburg, South Africa were assessed for
tuberculosis using point-of-care Xpert. Sputum smear microscopy and liquid culture were performed as reference standards.
Xpert-negatives were evaluated clinically, and further assessed at the discretion of clinicians. Participants were followed for
six months.
Results: From July-September 2011, 641 tuberculosis suspects were enrolled, of whom 69% were HIV-infected. Eight
percent were positive by a single Xpert. Among 116 individuals diagnosed with TB, 66 (57%) were Xpert negative, of which
44 (67%) were empirical or radiological diagnoses and 22 (33%) were Xpert negative/culture-positive. The median time to
tuberculosis treatment was 0 days (IQR: 0–0) for Xpert positives, 14 days (IQR: 5–35) for those diagnosed empirically, 14 days
(IQR: 7–29) for radiological diagnoses, and 144 days (IQR: 28–180) for culture positives. Xpert negative tuberculosis cases
were clinically similar to Xpert positives, including HIV status and CD4 count, and had similar treatment outcomes including
mortality and time to antiretroviral treatment initiation.
Conclusions: In a high HIV-burden setting, a single Xpert identified less than half of those started on tuberculosis treatment,
highlighting the complexity of TB diagnosis even in the Xpert era. Xpert at point-of-care resulted in same day treatment
initiation in Xpert-positives, but had no impact on tuberculosis treatment outcomes or mortality.
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Introduction
Access to rapid and accurate diagnosis of tuberculosis (TB)
remains a barrier to TB control–globally only 65% of TB cases
were diagnosed in 2011 [1]. The Xpert MTB/RIF assay (Xpert)
represents a potential revolution in TB diagnosis, with good
accuracy, rapid time to results and the possibility of decentralized
implementation close to the point-of-care [2–4]. The World
Health Organization has endorsed the use of Xpert as the initial
diagnostic in individuals suspected of HIV-associated TB or
MDR-TB, or as a follow-on test to sputum smear microscopy [5].
South Africa has committed to a national scale-up of Xpert,
with the ultimate goal of screening all adult pulmonary TB
suspects with a single Xpert performed at a centralized labora-
tories [6]. Implementing Xpert at the point-of-care has been
demonstrated to be safe in terms of infection control [7], and has
the potential for same day treatment initiation [8], though may be
more expensive than placement in a central laboratory [9].
Moving the test away from the point-of-care could result in delays
to results that decrease the potential patient-level impact of Xpert
[10]. Few data are available on the impact of Xpert at point-of-
care on time to treatment and patient outcomes. Furthermore,
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although Xpert has a higher sensitivity than smear microscopy
[3,11,12], reliance on a single Xpert may result in a substantial
number of missed TB cases. The few studies presenting diagnostic
information on Xpert negative individuals suggest that smear
microscopy and chest x-ray have limited utility in detecting culture
positive, Xpert negative TB [13,14].
Using operational data collected during the course of routine
clinical care at a primary care clinic in South Africa, we sought to
describe the diagnostic follow-up, clinical characteristics and




Witkoppen Health and Welfare Centre (WHWC) is a high-
volume primary health clinic primarily serving informal settlement
communities in northern Johannesburg, South Africa. Since 2011,
all patients presenting at the clinic were routinely tested for HIV
and screened for the presence of TB symptoms. Consecutive TB
suspects who consented were enrolled into this prospective cohort
study. As part of the WHWC routine diagnostic process, all TB
suspects also were assessed by fluorescent sputum smear micros-
copy for acid-fast bacilli and liquid culture for M. tuberculosis,
performed at a centralized National Health Laboratory Service
laboratory. In addition, Xpert was performed as a research
procedure at point-of-care by a low-skilled health care worker. All
results, including Xpert, were used for clinical decision making.
Patients with a TB diagnosis received TB treatment at WHWC,
and TB/HIV co-infected individuals were eligible for antiretro-
viral treatment (ART), while among those without TB co-infection
the ART treatment threshold was #350 cells/mm3. As part of
routine care and independent of study participation, Xpert
negative TB suspects were treated with a course of antibiotics if
clinically indicated, and asked to return for follow-up after one
week. At follow-up, Xpert negative TB suspects were evaluated
clinically, and had additional diagnostic testing (chest xray and a
second Xpert) at the discretion of the clinician. Chest x-rays were
performed at a nearby clinic. Chest x-ray results were classified as
positive when the radiologist’s report stated the x-ray was
suggestive of TB.
Demographic and clinical characteristics as well as laboratory
findings were collected through chart review. The clinical status of








(n = 591) p value (n = 641)
Age, median (IQR) 34 (29–39) 36 (29–44) 0.108 35 years (29–44)
Female gender (%) 23(46) 392 (66) 0.004 415 (65)
Non-South African nationality (%) 19 (38) 260 (44) 0.412 223 (35)
History of TB (%) 5 (10) 57 (10) 0.935 62 (10)
Presenting TB symptom
Cough (%) 49 (98) 569 (96) 0.529 618 (96)
Loss of weight(%) 30 (60) 188 (32) ,0.001 218 (34)
Fever (%) 5 (10) 38 (6) 0.333 43 (7)
Night sweats(%) 33 (66) 181 (31) ,0.001 214 (33)
HIV status 0.026
Positive 43 (86) 400 (68) 443 (69)
Negative 6 (12) 156 (26) 162 (25)
Unknown 1 (2) 35 (6) 36 (6)
Among HIV positive
CD4 count, mean (95% CI) 179 cells/mm3 (128–230) 344 cells/mm3 (319–370) ,0.001 329 cells/mm3 (305–353)
CD4 count, median (IQR) 148 cells/mm3 (66–249) 288 cells/mm3 (151–487) ,0.001 276 cells/mm3 (138–458)
CD4 count category 0.001
CD4#200 cells/mm3 (%) 24 (56) 126 (32) 152 (34)
CD4 201–350 cells/mm3 (%) 10 (20) 99 (25) 109 (25)
CD4 351–500 cells/mm3 (%) 3 (6) 71 (18) 74 (17)
CD4.500 cells/mm3 (%) 2 (4) 92 (23 94 (21)
CD4 missing (%) 4(9) 10 (3) 14 (3)
On ART at first suspect visit (%) 4 (9) 198 (45) ,0.001 202 (45)
Time on ART, median (IQR) 23 months 21 months (11–35) 0.606 21 months
(14–25) (11–35) (12–35)
Abbreviations: TB, tuberculosis; IQR, interquartile range; CI, confidence interval; ART, antiretroviral therapy.
doi:10.1371/journal.pone.0065421.t001
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participating Xpert negative TB suspects was determined through
chart review and/or telephone calls at two months from the initial
Xpert test, and again at six months for those who remained
symptomatic or could not be contacted at two months. Patients
lost to follow-up were traced in the national death registry.
Treatment outcomes at six months were determined for all those
initiated on TB treatment.
Definitions
The TB suspect definition was stratified by HIV status. For
HIV-infected or unknown status: cough, fever, night sweats,
weight loss of any duration; for HIV-uninfected: cough or fever $
two weeks, or night sweats or weight loss of any duration.
The basis for the decision to initiate TB treatment was defined
as the earliest positive diagnostic test (smear, culture, Xpert or
xray), or an empiric diagnosis if treatment was started in absence
of or prior to any positive diagnostic test.
TB suspects were classified as confirmed TB if smear microscopy,
culture or Xpert were positive, independent of whether TB
treatment was initiated. TB suspects were classified as possible TB if
started on treatment in the absence of mycobacteriological
confirmation (i.e. Xpert negative, smear negative or missing and
culture negative, missing or contaminated). TB suspects were
classified as not TB if culture, smear and Xpert were negative and
TB treatment was not started, or if the clinical outcome was good
in the absence of TB treatment among those with missing or
contaminated culture results.
Time to treatment was defined as the time from the baseline
visit, when the initial Xpert test was performed, until initiation of
TB treatment, whether at WHWC or elsewhere.
Statistical Analysis
Standard descriptive statistics were used to characterize the
cohort. Multinomial logistic regression was used to estimate odds
ratios and their 95% confidence intervals (CI) for the association
between baseline characteristics and the Xpert result among TB
cases (both definite and possible), using those -classified as not TB
as the referent population. Predictors with significance p,0.10 in
the univariate analysis were included in the multivariate model.
Poisson regression with robust error variance was used to compare
characteristics among Xpert positive and negative TB cases, as
well as among confirmed and possible TB cases [15]. Time to
treatment was compared by basis of TB treatment initiation using
Figure 1. Flow chart of diagnostic assessment and basis of TB treatment initiation in 641 TB suspects presenting to a primary care
clinic in Johannesburg, South Africa. The basis of diagnosis was defined as the earliest positive diagnostic test (smear, culture, Xpert or x-ray), or
an empiric diagnosis if treatment was started in absence of or prior to any positive diagnostic test. Abbreviation: TB, tuberculosis; Neg, negative; Pos,
positive; Cont, contaminated; NTM, non-tuberculous mycobacteria; ND, not done.
doi:10.1371/journal.pone.0065421.g001
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Kaplan-Meier curves and the log-rank test. All statistical analyses
were conducted using Stata 12 (StataCorp, College Station, TX).
Ethics Statement
This study was approved by institutional review boards at the
University of North Carolina, Chapel Hill and the University of
the Witwatersrand in Johannesburg, South Africa. All participants




Between July 15 and September 22, 2011, 641 consecutive TB
suspects were consented and enrolled into the study. The median
age was 35 years (IQR: 29–44), 65% were female, and 35% were
of non-South African nationality, with the majority (73%) from
Zimbabwe (see Table 1). Sixty-nine percent were HIV-infected, of
whom 45% were on ART at the baseline visit for a median of 21
months (IQR: 12–35). Among those not on ART, the majority
(174/280, 62%) were eligible for treatment, with a CD4 count of
#350 cells/mm3. The most common presenting TB symptom was
cough (97%), followed by night sweats (34%).
Diagnostic Follow-up and TB Diagnosis
The initial Xpert was positive in 8% (50/641) of TB suspects
(Figure 1). Among these, 32% (16/50) had a positive smear and
culture, 52% (26/50) were smear-negative/culture-positive, 4%
(2/50) were culture-negative and 12% (6/50) had missing or
unreported laboratory results. Among the 551 TB suspects with a
valid culture result, the sensitivity of a single Xpert compared to
culture was 66% (95% CI: 53–77%) and the specificity was 99%
(95% CI: 98–100%).
The initial Xpert was negative in 92% of suspects (591/641).
Among these, 72% were prescribed antibiotic treatment at the
baseline visit, with 66% receiving amoxicillin, 17% erythromycin,
11% amoxicillin/clavulanate potassium, and 6% another antibi-
otic. Among Xpert negative TB suspects, smear microscopy and
liquid culture were performed in the majority (98%) of patients,
chest x-ray in 15% and a second Xpert in 8%. Culture was
positive in 4% of Xpert-negatives (22/591), while smear micros-
copy was positive in only 1/591 (0.2%). Chest x-ray was
performed in 84 and suggestive for TB in 26 (31%), and a second
Table 3. Poisson regression models with robust error comparing characteristics among 50 Xpert positive and 66 negative TB
diagnoses.
Univariate Multivariate
Characteristic RR (95% CI) p value aRR (95% CI) p value
SA nationality REF
Non SA nationality 1.03 (0.67–1.60) 0.880
No history of TB REF
History of TB 0.88 (0.43–1.82) 0.730
Age #35 years REF REF
Age .35 years 0.61 (0.39–0.95) 0.030 0.60 (0.36–0.98) 0.042
Female gender REF REF
Male gender 1.30 (0.85–1.99) 0.200 1.28 (0.81–2.02) 0.290
HIV status
Negative REF REF
Positive 0.70 (0.40–1.23) 0.214 0.68 (0.39–1.17) 0.164
Unknown 0.42 (0.07–2.47) 0.335
CD4 count
CD4,200 REF REF
CD4$200 1.06 (0.66–1.72) 0.807 1.32 (0.49–3.51) 0.583
No ART REF
ART 0.57 (0.23–1.380 0.211
TB Symptoms
No loss of weight REF REF
Loss of weight 1.50 (0.97–2.32) 0.068 1.25 (0.79–2.01) 0.337
No night sweats REF
Night sweats 1.23 (0.78–1.93) 0.369
Cough REF
No cough 0.45 (0.08–2.67) 0.381
No fever REF
Fever 1.06 (0.53–2.11) 0.867
Abbreviations: TB, tuberculosis; ART, antiretroviral treatment; RR, relative risk; aRR, adjusted relative risk; REF, reference.
doi:10.1371/journal.pone.0065421.t003
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Xpert was requested in 49 and positive in 2. In addition, non-
tuberculous mycobacteria grew in the sputum cultures of 2 (4%)
Xpert negative TB suspects.
Overall, 11% (66/591) Xpert-negative TB suspects were
classified as TB cases, of which 35% were confirmed cases (22
culture-positive, 1 smear-positive culture-negative and 65%
possible TB cases (18 radiological diagnosis and 25 clinical
diagnosis).
Factors Associated with TB Diagnosis
Among 641 TB suspects, the odds of receiving a TB diagnosis
was higher if HIV-infected (aOR 7.22 [95% CI: 2.71–19.22] for
Xpert-positives and aOR 18.96 [95% CI: 6.42–55.98] for Xpert-
negatives), or ART-naı̈ve (aOR 5.6 [95% CI: 1.78–17.24] for
Xpert-positives and aOR 2.70 [95% CI: 1.43–5.55] for Xpert-
negatives) and (Table2). The presence of night sweats (aOR 2.61
[95%I 1.28–5.30] and loss of weight (aOR 2.29 [1.16–4.52] was
associated with having a positive Xpert, while night sweats was the
Figure 2. Time to TB treatment in 114 TB cases, by basis of TB treatment initiation. Kaplan-Meier curves showing time to treatment
stratified by basis of TB diagnosis, excluding those diagnosed based on 2nd Xpert or sputum smear microscopy (n = 2). The median time to treatment
and IQR for each basis of TB treatment initiation are listed. Abbreviation: TB, tuberculosis.
doi:10.1371/journal.pone.0065421.g002
Figure 3. Two and six-month outcomes of 591Xpert-negative TB suspects and 50 Xpert-positive TB suspects presenting to a
primary care clinic in Johannesburg, South Africa. Abbreviations: LTFU, lost to follow-up; TB, tuberculosis; mo, month; Rx, treatment.
doi:10.1371/journal.pone.0065421.g003
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only significant presenting symptom associated with an Xpert-
negative TB diagnosis (aOR 3.01 [95% CI: 1.67–5.41]). A higher
CD4 count was associated with a lower odds of a TB diagnosis, but
this was only significant among Xpert-negative TB suspects (aOR
0.14 to 0.37).
Among the 116 TB cases, age was the only factor associated
with a positive Xpert result, with those over 35 years being 40%
less likely to have Xpert positive TB compared to Xpert negative
TB (aRR 0.60 [95% CI: 0.36–0.98]) (Table 3). Compared to those
with confirmed TB, possible TB s were more likely to be HIV-
infected (98% vs 82%, p 0.028), but were similar on other clinical
characteristics, including demographics, CD4 count, HAART use
and TB symptoms in univariate and multivariate regression
analysis (results not shown).
Among culture-positive TB cases, individuals testing Xpert-
negative had significantly longer time to culture positivity
compared to Xpert-positives (median of 23 days [IQR: 18–32]
versus 12 days [IQR: 10–16], p,0.001).
TB Treatment Initiation
In total, 106 of the 116 TB caseswere started on TB treatment
by six months following the initial Xpert assay. Almost all (48/50,
96%) Xpert positive patients started treatment, 2 were lost to
follow-up., The proportion of Xpert-negative TB cases starting TB
treatment was 70% (14/20) of culture positives, 95% (18/19) of
individuals with suggestive chest x-ray, 100% (1/1) with positive
2nd Xpert, and 0% (0/1) with positive smear microscopy. In
addition, 25 individuals started empiric TB treatment. The
median time to TB treatment was 0 days (IQR: 0–0) for those
positive on the initial Xpert, 14 days (IQR: 5–35) for empiric TB,
14 days (IQR: 7–29) for those starting treatment based on
suggestive chest x-ray findings, and 144 days (IQR: 28–180) for
culture positive, Xpert-negative patients (see Figure 2).
Two and Six Month Follow-up
Among TB suspects with a negative initial Xpert, 18% had
persistent TB symptoms at two months of follow-up, but only 3%
remained symptomatic at six months (see Figure 3). The
prevalence of persistent symptoms was similar between possible
and confirmed TB cases, with 14% of possible and 18% of
confirmed cases having symptoms at two months (p = 0.121), and
1% of possible and 0% of confirmed TB cases having TB
symptoms at six months follow-up (p = 0.072). TB treatment
outcomes between Xpert-positive and negative TB cases were not
different (p 0.460). Among the 48 Xpert-positive cases started on
treatment, 48% had a successful treatment outcome (six month
treatment completion or cure), 25% transferred out, 23%
defaulted, 2% were still on treatment and 2% died. Among the
58 Xpert-negative patients started on treatment, 64% completed
or cured, 19% transferred, 12% defaulted, 3% still on treatment,
and 2% died. Among TB suspects classified as not having TB, 1%
died (3/535). TB treatment outcomes were also similar between
confirmed and possible TB cases (p = 0.262).
During follow-up, a similar proportion of HIV co-infected
Xpert positive individuals (55%) started ART as co-infected Xpert
negatives (51%, p 0.130). The median time to starting ART was
similar among Xpert positives, Xpert negative TB patients and
those without TB (23 days [IQR: 16–56], 24 days [IQR: 19–54]
and 22 days [IQR: 14–31] respectively).
Discussion
In this prospective cohort of TB suspects with high HIV
prevalence screened by Xpert at point-of-care, 8% tested positive
on initial Xpert and an additional 4% were bacteriologically
confirmed with TB on culture, smear or second Xpert. Surpris-
ingly less than half of those initiated on TB treatment had a
positive Xpert result on initial screening, and 41% initiated
treatment based on clinical or radiological findings alone.
Those diagnosed with TB were more likely to be HIV-infected,
ART-naive, have a lower CD4 count and present with more
symptoms, as could be expected in a setting with high HIV
prevalence [16]. Xpert-negative, culture-positive TB cases had a
lower sputum bacillary burden, with significantly longer time to
culture positivity compared to Xpert-positives. Xpert-negative TB
cases were similar to Xpert-positive cases on most clinical
characteristics, including HIV status, CD4 count and ART use.
This is in contrast to findings from Cape Town, where Xpert-
negative TB cases had less advanced immunosuppression com-
pared to Xpert-positive cases [13]. Differences in the study
populations may partially explain the discrepancy. Our study
population was more heterogeneous in terms of HIV infection,
level of immunosuppression and ART experience, and thus more
generalizable to the target population for Xpert testing according
to the South African implementation strategy than the population
studied by Lawn et al, which was restricted to ART-eligible HIV-
infected persons regardless of TB symptoms.
Point-of-care Xpert did afford a clear advantage to patients in
terms of time to TB treatment initiation. Almost all TB suspects
testing Xpert-positive were started on TB treatment the same day
as presenting with TB symptoms. This was two weeks faster than
Xpert-negative suspects who started empirically or based on
suggestive chest x-ray, and 20 weeks faster than those diagnosed by
culture. Only 70% of those diagnosed based on culture were ever
started on treatment, as some patients did not return to the clinic
following the long delay for results, which is consistent with
findings from other clinics in South Africa [17]. Furthermore, 12%
of all culture results were either contaminated, not reported, or
otherwise missing, highlighting the limited clinical value of culture.
Despite this faster TB treatment initiation, Xpert-negatives had
similar six-month TB treatment outcomes, including mortality,
confirming findings by Lawn et al [13] and Yoon et al [18], and
time to antiretroviral treatment initiation.
Xpert-negative TB cases who started treatment based on
clinical or radiological criteria only were more likely to be HIV-
infected, but were otherwise clinically similar to bacteriologically
confirmed cases. This likely reflects a clinician’s decision to initiate
TB treatment in the absence of a positive confirmatory diagnostic
in HIV-infected individuals to avoid the high mortality of
untreated TB in this population [19]. The finding that more than
half of all patients starting TB treatment were Xpert-negative, and
41% started TB treatment based on radiological or clinical
findings was surprising given the high sensitivity of Xpert in this
population. These results are similar to a cohort of TB suspects
screened by sputum microscopy, in which 44% of TB cases at an
HIV clinic in South Africa started treatment based on a suggestive
chest x-ray [20]. These findings emphasize the need for evidence-
based assessment strategies for Xpert-negative TB suspects.
Our findings should be interpreted taking several limitations
into account. Firstly, we studied a single primary care center with a
clinical decision making process and access to diagnostic testing
that may not be representative of all clinics in South Africa or
other regions. Secondly, the observed time to treatment and
proportion of patients started on treatment likely represents a
‘‘best case’’ scenario and may not be generalizable to settings
where Xpert is performed at centralized laboratories. Thirdly,
even though cultures were negative in almost all patients started on
treatment based on clinical or radiological suspicion, we cannot
Patient Impact of Point-of-Care Xpert
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exclude the presence of sputum culture-negative TB in these
individuals, and that some patients started on treatment may not
have had TB. Finally, our assessment of the impact of Xpert at
point-of-care on treatment outcomes was limited by small sample
size and relatively high (15%) loss to follow-up.
Conclusions
This operational research, the first to assess the operational
impact of the 2010 recommendation for use of Xpert as the initial
diagnostic highlights the diagnostic advantage of Xpert at point-of-
care as this results in same day treatment initiation, the low
mortality among Xpert-negative TB suspects, and the inadequacy
of culture and x-ray in terms of speed and accuracy, respectively,
for the assessment of Xpert-negative TB suspects. The prevalence
of treatment without bacteriological confirmation reflects the
complexity of TB diagnosis, even in the Xpert era. Future research
should focus on optimizing assessment strategies of Xpert-negative
TB suspects, accounting for setting specific factors such as HIV co-
infection, laboratory capacity and cost concerns, to ensure the
ultimate goal of improved patient outcomes through rapid and
accurate diagnosis in all TB suspects.
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